Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antidepressant therapy: benefits and risks in perspective.

G D Burrows, T R Norman, L Dennerstein

    Acta Psychiatrica Scandinavica. Supplementum
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Corrigendum to "Spinal surgery trials in high-, middle- and low-income countries over the past two decades" [Brain Spine 2 (Supplement 2) (2022) 101360].

    Brain & spine·2025
    Same author

    Chronic subdural haematoma: the role of peri-operative medicine in a common form of reversible brain injury.

    Anaesthesia·2022
    Same author

    Major trauma care at a regional trauma centre during the COVID-19 lockdown in England.

    Annals of the Royal College of Surgeons of England·2021
    Same author

    Incidence of chronic subdural haematoma: a single-centre exploration of the effects of an ageing population with a review of the literature.

    Acta neurochirurgica·2021
    Same author

    Chlorhexidine dressings could reduce external ventricular drain infections: results from a systematic review and meta-analysis.

    The Journal of hospital infection·2021
    Same author

    Low body mass index is associated with increased mortality in patients with pelvic and acetabular fractures.

    Injury·2021
    Same journal

    Use of psychotropic drugs during pregnancy and breast-feeding.

    Acta psychiatrica Scandinavica. Supplementum·2015
    Same journal

    Getting depression clinical practice guidelines right: time for change?

    Acta psychiatrica Scandinavica. Supplementum·2013
    Same journal

    Manipulating melatonin in managing mood.

    Acta psychiatrica Scandinavica. Supplementum·2013
    Same journal

    Chronobiology of mood disorders.

    Acta psychiatrica Scandinavica. Supplementum·2013
    Same journal

    It is time we managed depression: the emerging role of chronobiology. Preface.

    Acta psychiatrica Scandinavica. Supplementum·2013
    Same journal

    Lifestyle management of unipolar depression.

    Acta psychiatrica Scandinavica. Supplementum·2013
    See all related articles

    Second-generation antidepressants like mianserin and nomifensine offer improved safety and efficacy over older tricyclics. Their therapeutic benefits appear to outweigh risks of rare severe side effects, making them valuable treatment options.

    Area of Science:

    • Pharmacology and Therapeutics
    • Clinical Psychiatry

    Background:

    • Tricyclic antidepressants (TCAs) have historically been a cornerstone of depression treatment.
    • Limitations of TCAs include a narrow therapeutic index, significant side effects, and potential for cardiotoxicity.
    • The development of second-generation antidepressants aimed to overcome these limitations.

    Purpose of the Study:

    • To evaluate the safety and efficacy of mianserin and nomifensine compared to tricyclic antidepressants.
    • To assess whether these newer agents achieve the goals of being safer, faster-acting, and having fewer side effects.

    Main Methods:

    • Review of existing clinical data and studies on mianserin and nomifensine.
    • Comparative analysis of adverse event profiles and therapeutic outcomes.

    Related Experiment Videos

  • Assessment of pharmacological properties influencing efficacy and safety.

    • Main Results:

    • Mianserin and nomifensine demonstrate advantages in terms of safety and side effect profiles compared to TCAs.
    • While rare severe adverse effects exist (blood dyscrasias for mianserin, fever for nomifensine), they are considered manageable.
    • Therapeutic gains achieved by these second-generation antidepressants are significant.

    Conclusions:

    • Mianserin and nomifensine represent a therapeutic advancement in antidepressant pharmacotherapy.
    • The benefits of these agents generally outweigh the risks associated with their use.
    • These drugs offer a viable alternative for patients seeking improved depression management with a better safety profile.